|
Subgroup
|
Reference
|
SOR
|
Tests for heterogeneity
|
|---|
|
(95% CI)
|
Q
|
P
|
I
2(%)
|
|---|
|
Geographic region
| | | | | |
|
Asia
|
[17, 19, 23, 25]
|
1.05 (1.03-1.08)△
|
30.7
|
<0.001*
|
90
|
|
Asia#
|
[19, 23, 25]
|
1.04 (1.01-1.06)△
|
1.76
|
0.42
|
0.00
|
|
Western
|
[18, 26, 27]
|
1.17 (1.11-1.22)△
|
0.64
|
0.724
|
0.00
|
|
Population
| | | | | |
|
Healthy people
|
[16, 17, 20, 28]
|
2.59 (2.07-3.23)▲
|
6.08
|
0.02*
|
69
|
|
Diabetic
|
[18, 24]
|
1.90 (1.30-2.78)▲
|
0.07
|
0.79
|
0
|
|
Sex
| | | | | |
|
Male
|
[21, 22, 26]
|
1.43 (1.05-1.94)△
|
32.98
|
0.001*
|
94
|
|
Female
|
[21, 22, 26]
|
1.21 (1.04-1.41)△
|
4.57
|
0.07
|
63
|
|
Follow-up
| | | | | |
|
<5 years
|
[2, 19, 23, 25]
|
1.03 (1.01-1.06)△
|
0.19
|
0.66
|
0
|
|
[16, 17]
|
2.49 (1.79-3.46)▲
|
2.99
|
0.08
|
67
|
|
≥5 years
|
[17, 18, 26, 27]
|
1.09 (1.04-1.14)△
|
2.63
|
0.45
|
0
|
|
[18, 20, 24, 28]
|
2.64 (2.09-3.32)▲
|
6.48
|
0.09
|
54
|
- SOR: summary odds ratio; #Studies in Asian areas (except study by Chang et al. [17]); △OR calculated using continuous variables; per 1 mg/dL increase of uric acid levels; ▲OR calculated using dichotomous variables; hyperuricemia compared with normal; *heterogeneity exists.
